Andere Sprachen BioMarin Pharmaceutical Inc.

Aktien

924801

US09061G1013

BMRN

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 10.05.2024			% 5 Tage	% 1. Jan.
81,03 ^USD	-0,84 %		-1,71 %	-15,96 %

06.05.	Biomarin Pharmaceutical Insider verkaufte Aktien im Wert von $414.550, laut einer aktuellen SEC Einreichung	MT
04.05.	Biomarin Pharmaceutical Inc. gibt positive neue Daten bekannt, die die Sicherheit und Wirksamkeit von VOXZOGO® (Vosoritid) bei Kindern unterstützen	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

BioMarin to Present at the BofA Securities 2024 Health Care Conference on Wednesday, May 15 at 10:00am PT 1:00pm ET, in Las Vegas, NV	09.05.
BioMarin to Present at the BofA Securities 2024 Health Care Conference on Wednesday, May 15 at 10:00am PT / 1:00pm ET, in Las Vegas, NV	08.05.
Biomarin Pharmaceutical Insider Sold Shares Worth $414,550, According to a Recent SEC Filing	06.05.
New Data for BioMarin's VOXZOGO for Multiple Growth-Related Conditions in Children Presented at Pediatric Endocrine Society Annual Meeting	06.05.
Biomarin Pharmaceutical Inc. Announces Positive New Data Supporting the Safety and Efficacy of VOXZOGO® in Children	04.05.
BioMarin Pharmaceutical Inc. Announces That Positive New Data Supporting the Safety and Efficacy of VOXZOGO® in Children	04.05.
RACCOMANDAZIONI DEGLI ANALISTI USA/UK : Alphabet, Amgen, Starbucks, PayPal, Moderna...	03.05.
RECOMENDACIONES DE LOS ANALISTAS EE.UU./UK : Alphabet, Amgen, Starbucks, PayPal, Moderna...	03.05.
ANALYST RECOMMENDATIONS : Alphabet, Amgen, Starbucks, PayPal, Moderna...	03.05.
BioMarin Pharmaceutical Investors Overfocused on Roctavian, Distracted From Enzyme Replacement Therapies, UBS Says	29.04.
BioMarin Pharmaceutical Q1 Non-GAAP EPS, Revenue Increase -- Shares Down After Hours	24.04.
BioMarin: Q1 Earnings Snapshot	24.04.
(BMRN) BIOMARIN PHARMACEUTICAL Forecasts Fiscal Year 2024 EPS Range $2.75 - $2.95	24.04.
Earnings Flash (BMRN) BIOMARIN PHARMACEUTICAL Posts Q1 Revenue $648.8M	24.04.
Earnings Flash (BMRN) BIOMARIN PHARMACEUTICAL Posts Q1 EPS $0.71	24.04.
BioMarin Pharmaceutical Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	24.04.
BioMarin Reports Record Financial Results for the First Quarter 2024	24.04.
Biomarin Pharmaceutical Inc. Reaffirms Earnings Guidance for the Year 2024	24.04.
BioMarin Pharmaceutical : IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE - Form 8-K	23.04.
BioMarin Pharmaceutical Investors to Focus Q1 on Strategic Review, Cost-Cutting Measures, UBS Says	22.04.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen BioMarin Pharmaceutical Inc.

Aktien

924801

US09061G1013

BMRN

Andere Sprachen

Filter